273 related articles for article (PubMed ID: 23697804)
21. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.
Jia Q; Bowen R; Sahakian J; Dillon BJ; Horwitz MA
Infect Immun; 2013 May; 81(5):1550-61. PubMed ID: 23439306
[TBL] [Abstract][Full Text] [Related]
22. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
[No Abstract] [Full Text] [Related]
23. [Immunobiological properties of recombinant atoxic forms of the Pseudomonas aeruginosa exotoxin A].
Isakov MA; Soldatenkova AS; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):37-42. PubMed ID: 21598613
[TBL] [Abstract][Full Text] [Related]
24. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
[TBL] [Abstract][Full Text] [Related]
25. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
[TBL] [Abstract][Full Text] [Related]
26. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
Eyles JE; Hartley MG; Laws TR; Oyston PC; Griffin KF; Titball RW
Microb Pathog; 2008 Feb; 44(2):164-8. PubMed ID: 17904793
[TBL] [Abstract][Full Text] [Related]
27. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain.
Straskova A; Cerveny L; Spidlova P; Dankova V; Belcic D; Santic M; Stulik J
Microbes Infect; 2012 Feb; 14(2):177-87. PubMed ID: 21930232
[TBL] [Abstract][Full Text] [Related]
28. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent
Jia Q; Horwitz MA
Front Cell Infect Microbiol; 2018; 8():154. PubMed ID: 29868510
[No Abstract] [Full Text] [Related]
29. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
Sebastian S; Dillon ST; Lynch JG; Blalock LT; Balon E; Lee KT; Comstock LE; Conlan JW; Rubin EJ; Tzianabos AO; Kasper DL
Infect Immun; 2007 May; 75(5):2591-602. PubMed ID: 17296751
[TBL] [Abstract][Full Text] [Related]
30. Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia.
Chiavolini D; Weir S; Murphy JR; Wetzler LM
Clin Vaccine Immunol; 2008 Sep; 15(9):1322-9. PubMed ID: 18614668
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
Green M; Choules G; Rogers D; Titball RW
Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge.
Cong Y; Yu JJ; Guentzel MN; Berton MT; Seshu J; Klose KE; Arulanandam BP
Vaccine; 2009 Sep; 27(41):5554-61. PubMed ID: 19651173
[TBL] [Abstract][Full Text] [Related]
33. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component.
Wetter M; Kowarik M; Steffen M; Carranza P; Corradin G; Wacker M
Glycoconj J; 2013 Jul; 30(5):511-22. PubMed ID: 23053636
[TBL] [Abstract][Full Text] [Related]
34. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.
Feldman MF; Wacker M; Hernandez M; Hitchen PG; Marolda CL; Kowarik M; Morris HR; Dell A; Valvano MA; Aebi M
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):3016-21. PubMed ID: 15703289
[TBL] [Abstract][Full Text] [Related]
35. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
36. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
Ho MM; Bolgiano B; Martino A; Kairo SK; Corbel MJ
Hum Vaccin; 2006; 2(3):89-98. PubMed ID: 17012902
[TBL] [Abstract][Full Text] [Related]
37. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults.
Konadu EY; Parke JC; Tran HT; Bryla DA; Robbins JB; Szu SC
J Infect Dis; 1998 Feb; 177(2):383-7. PubMed ID: 9466525
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.
Hatz CF; Bally B; Rohrer S; Steffen R; Kramme S; Siegrist CA; Wacker M; Alaimo C; Fonck VG
Vaccine; 2015 Aug; 33(36):4594-601. PubMed ID: 26162850
[TBL] [Abstract][Full Text] [Related]
39. PglB function and glycosylation efficiency is temperature dependent when the pgl locus is integrated in the Escherichia coli chromosome.
Terra VS; Mauri M; Sannasiddappa TH; Smith AA; Stevens MP; Grant AJ; Wren BW; Cuccui J;
Microb Cell Fact; 2022 Jan; 21(1):6. PubMed ID: 34986868
[TBL] [Abstract][Full Text] [Related]
40. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
Bakshi CS; Malik M; Mahawar M; Kirimanjeswara GS; Hazlett KR; Palmer LE; Furie MB; Singh R; Melendez JA; Sellati TJ; Metzger DW
Vaccine; 2008 Sep; 26(41):5276-88. PubMed ID: 18692537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
